New therapeutic approaches in breast cancer

Davies, Eleri-Lloyd; Hiscox, Stephen Edward

doi:10.1016/j.maturitas.2010.10.012

Cited by 37 publications

(29 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 There are several pathways involved in the modulation of breast cancer and its progression to metastasis. [4][5][6] There has been progress made in understanding the biological behavior of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER-2) for multiple subtypes of breast cancer. Nanoparticles (NPs) carrying anticancer agents can be delivered actively or passively to targeted tumor to serve in diagnosis and treatment of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

“…7 NPs size and distribution are measured by photon correlation spectroscopy and verified by scanning or transmission electron microscopy (TEM) to determine the diameter of the particles. 4 This technology of drug delivery using nanometer-sized particles could be the major therapeutic approach for future cancer patients. A recent progress in drug delivery technology is the design of surface-modified NPs that can improve the poor specificity and toxicological problems of antitumor therapy and act as a major therapeutic approach for patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Drug delivery approaches for breast cancer

Singh

Lillard

et al. 2017

IJN

178

View full text Add to dashboard Cite

Breast cancer is one of the most common cancers affecting women worldwide. The controlled release of drugs to the precise site of the disease using a nanocarrier vehicle increases the therapeutic efficiency of the drugs. Nanotechnology-based approaches used to endorse clinical improvement from a disease also help to understand the interaction of malignant cells with their microenvironment. Receptor-based targeting is another approach for drug delivery which is undergoing clinical trials. Nanoparticles (NPs) delivery has been proven to promise high loading capacity, less toxicity, and stability of the drugs or biomolecules compared to traditional chemotherapeutic drugs. The goal of this review is to present the current problems of breast cancer therapy and discuss the NP-based targeting to overcome the hurdles of conventional drug therapy approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Drug delivery approaches for breast cancer

Singh

Lillard

et al. 2017

IJN

178

View full text Add to dashboard Cite

show abstract

“…Estrogen receptor alpha (ERα) is a well-studied member of the nuclear receptor (NR) superfamily and is a key hormone-regulated transcription factor (TF) in three-quarters of breast cancer cases (1). The activation of ERα through 17β-estradiol (referred to as estradiol or E2) results in the translocation of the receptor from the cytoplasm to the nucleus and strengthens the binding of the receptor and its collaborating factors to regulatory regions of DNA.…”

Section: Introductionmentioning

confidence: 99%

Inducible super-enhancers are organized based on canonical signal-specific transcription factor binding elements

2016

View full text Add to dashboard Cite

Super-enhancers are established through the interactions of several enhancers and a large number of proteins, including transcription factors and co-regulators; however, the formation of these interactions is poorly understood. By re-analysing previously published estrogen receptor alpha (ERα) ChIP-seq data sets derived from the MCF-7 cell line, we observed that in the absence of stimulation, future super-enhancers are represented by one or a few transcription factor binding event(s) and these extraordinary enhancers possess a response element largely specific to the ERα dimer. Upon hormonal stimulation, these primary binding sites are surrounded by a large amount of ERα and the critical components of active enhancers, such as P300 and MED1, and together with neighbouring sites bound by newly recruited ERα, they generate the functional super-enhancers. To further validate the role of canonical elements in super-enhancer formation, we investigated some additional signal-dependent transcription factors, confirming that certain, distinguished binding elements have a general organizer function. These results suggest that certain signal-specific transcription factors guide super-enhancer formation upon binding to strong response elements. These findings may reshape the current understanding of how these regulatory units assemble, highlighting the involvement of DNA elements instead of protein–protein interactions.

show abstract

“…Patterns of receptor expression on breast cancer cells are related to prognosis and are a major determinant of treatment decision making [2]. In breast cancer pathways modulating progression will form the basis for emerging targeted strategies for the treatment of metastatic disease [7].…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle delivery for metastatic breast cancer

Grobmyer¹,

Zhou²,

Gutwein³

et al. 2012

Maturitas

View full text Add to dashboard Cite

Breast cancer represents a major ongoing public health problem as the most common non-cutaneous malignancy among U.S. women. While significant progress has been made in improving loco-regional treatments for breast cancer, relatively little progress has been made in diagnosing and treating patients with metastatic breast cancer. At present there are limited curative options for patients with breast cancer metastatic beyond regional nodes. Emerging nanotechnologies promise new approaches to early detection and treatment of metastatic breast cancer. Fulfilling the promise of nanotechnologies for patients with metastatic breast cancer will require delivery of nanomaterials to sites of metastatic disease. Future translational approaches will rely on an ever increasing understanding of the biology of breast cancer subtypes and their metastases. These important concepts will be highlighted and elucidated in this manuscript.

show abstract

New therapeutic approaches in breast cancer

Cited by 37 publications

References 68 publications

Drug delivery approaches for breast cancer

Drug delivery approaches for breast cancer

Inducible super-enhancers are organized based on canonical signal-specific transcription factor binding elements

Nanoparticle delivery for metastatic breast cancer

Contact Info

Product

Resources

About